ABT · Earnings call · 2026Q3T · Full report
Regulatory Risk
ABBOTT LABORATORIES · 2026-10-21 · Importance 20 · Surprise 24 · In source text
Abbott said Cologuard Plus is a new test and that CMS reimbursement is being set through a process different from those for established tests, National Coverage Determinations, and some MedTech processes. The company is in active discussions with CMS, which management described as productive, and the CEO said he would be surprised if the reimbursement rate were reduced. No reimbursement amount or decision date was provided.
Key facts
- Abbott attributed about one percentage point of growth shortfall to a July cybersecurity event that caused approximately 7–10 days of disruption.
- Abbott said a couple of health-system accounts shut down connectivity after the cybersecurity event until Abbott provided evidence that systems were up to speed.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | realized | — | Abbott attributed about one percentage point of growth shortfall to a July cybersecurity event that caused approximately 7–10 days of… |